Kristen N Ganjoo

Sarcoma specialist

Associate Professor of Medicine (Oncology) at the Stanford University Medical Center
4.8 out of 5
139 Patient Ratings
15 Patient Comments

Cancer Center

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic » Getting Here » Make An Appointment

Gastrointestinal (GI) Cancer Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic » Getting Here » Make An Appointment

Sarcoma Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic » Getting Here » Make An Appointment

Professional Education

Board Certification: Medical Oncology, American Board of Internal Medicine (2000)

Fellowship: Indiana University School Of Medicine (2000) IN

Residency: Indiana University (1997) IN

Internship: Indiana University (1995) IN

Medical Education: University of South Alabama Medical Center (1994) AL

BS, UC Davis, Biological Sciences (1989)

Administrative Appointments

Assistant Professor of Medicine, Stanford University (2004 - Present)

Assistant Professor of Medicine, Indiana University (2000 - 2004)

Patient Ratings and Comments

4.9

Friendliness

4.8

Recommended to others

4.9

Explanations

4.8

Listens

4.8

Includes you in decisions

4.8

Clear Communication

4.8

Confidence in your doctor

4.3

Wait times

SHC Patient, Nov 2014

Dr. Ganjoo, her PA & RN are extraordinary people and very good at what they do!

SHC Patient, Oct 2014

I am very satisfied with all the spirit of services and attitude especially Dr. Ganjoo, Kristen N. ethics trusted and respected the spirit!

SHC Patient, Oct 2014

Left Stanford with a feeling that I would be in the best HANDS VA BAD.

SHC Patient, Sep 2014

Telephone call from the doctor on during holiday/decrease dosage, as promised by her nurse never happened. Off hour communication, such as by e-mails, was not good.

View all 15 patient comments

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma
Chawla, S. P., Cranmer, L. D., Van Tine, B. A., Reed, D. R., Okuno, S. H., & Ganjoo, K. N. (2014). Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma. JOURNAL OF CLINICAL ONCOLOGY, 32(29), 3299-?.

A Phase 2 Trial of R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor (IGF-1R), in Patients With Recurrent or Refractory Rhabdomyosarcoma, Osteosarcoma, Synovial Sarcoma, and Other Soft Tissue Sarcomas Results of a Sarcoma Alliance for Research Through Collaboration Study
Pappo, A. S., Vassal, G., Crowley, J. J., Bolejack, V., Hogendoorn, P. Cw., & Helman, L. J. (2014). A Phase 2 Trial of R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor (IGF-1R), in Patients With Recurrent or Refractory Rhabdomyosarcoma, Osteosarcoma, Synovial Sarcoma, and Other Soft Tissue Sarcomas Results of a Sarcoma Alliance for Research Through Collaboration Study. CANCER, 120(16), 2448-2456.

Gastrointestinal Stromal Tumors, Version 2.2014
von Mehren, M., Randall, R. L., Benjamin, R. S., Boles, S., Bui, M. M., & Sundar, H. (2014). Gastrointestinal Stromal Tumors, Version 2.2014. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 12(6), 853-862.

Soft Tissue Sarcoma, Version 2.2014 Featured Updates to the NCCN Guidelines
von Mehren, M., Randall, R. L., Benjamin, R. S., Boles, S., Bui, M. M., & Sundar, H. (2014). Soft Tissue Sarcoma, Version 2.2014 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 12(4), 473-483.

A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors ( GIST) following failure of at least imatinib and sunitinib
Ganjoo, K. N., Villalobos, V. M., Kamaya, A., Fisher, G. A., Butrynski, J. E., & George, S. (2014). A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors ( GIST) following failure of at least imatinib and sunitinib. ANNALS OF ONCOLOGY, 25(1), 236-240.

R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study
Pappo, A. S., Patel, S. R., Crowley, J., Reinke, D. K., Kuenkele, K.-P., & Baker, L. H. (2011). R1507, a Monoclonal Antibody to the Insulin-Like Growth Factor 1 Receptor, in Patients With Recurrent or Refractory Ewing Sarcoma Family of Tumors: Results of a Phase II Sarcoma Alliance for Research Through Collaboration Study. JOURNAL OF CLINICAL ONCOLOGY, 29(34), 4541-4547.

Current and Emerging Pharmacological Treatments for Gastrointestinal Stromal Tumour
Ganjoo, K. N., & Patel, S. (2011). Current and Emerging Pharmacological Treatments for Gastrointestinal Stromal Tumour. DRUGS, 71(3), 321-330.

A Phase I Study of the Safety and Pharmacokinetics of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma
Ganjoo, K. N., Cranmer, L. D., Butrynski, J. E., Rushing, D., Adkins, D., & Chawla, S. P. (2011). A Phase I Study of the Safety and Pharmacokinetics of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma. ONCOLOGY, 80(1-2), 50-56.

New Developments in Targeted Therapy for Soft Tissue Sarcoma
Ganjoo, K. N. (2010). New Developments in Targeted Therapy for Soft Tissue Sarcoma. CURRENT ONCOLOGY REPORTS, 12(4), 261-265.

Soft Tissue Sarcoma
Demetri, G. D., Antonia, S., Benjamin, R. S., Bui, M. M., Casper, E. S., & Wayne, J. (2010). Soft Tissue Sarcoma. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 8(6), 630-674.

NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors
Demetri, G. D., von Mehren, M., Antonescu, C. R., DeMatteo, R. P., Ganjoo, K. N., & Wayne, J. D. (2010). NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 8, S1-S43.

Antiangiogenesis Agents in the Treatment of Soft Tissue Sarcomas
Ganjoo, K., & Jacobs, C. (2010). Antiangiogenesis Agents in the Treatment of Soft Tissue Sarcomas. CANCER, 116(5), 1177-1183.

Trabectedin: an anticancer drug from the sea
Ganjoo, K. N., & Patel, S. R. (2009). Trabectedin: an anticancer drug from the sea. EXPERT OPINION ON PHARMACOTHERAPY, 10(16), 2735-2743.

Acute myeloid leukemia in patients with gastrointestinal stromal tumors treated with Gleevec
Ganjoo, K. N., Demetri, G. D., Jacobs, C., & Patel, S. (2009). Acute myeloid leukemia in patients with gastrointestinal stromal tumors treated with Gleevec. LEUKEMIA & LYMPHOMA, 50(11), 1882-1884.

Effects of denosumab on pain and analgesic use in giant cell tumor of bone: Interim results from a phase II study
Martin-Broto, J., Cleeland, C. S., Glare, P. A., Engellau, J., Skubitz, K. M., & Atchison, C. (2014). Effects of denosumab on pain and analgesic use in giant cell tumor of bone: Interim results from a phase II study. ACTA ONCOLOGICA, 53(9), 1173-1179.

Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.
Levy, R., Ganjoo, K. N., Leonard, J. P., Vose, J. M., Flinn, I. W., & Denney, D. W. (2014). Active idiotypic vaccination versus control immunotherapy for follicular lymphoma. Journal of clinical oncology , 32(17), 1797-1803.

Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404).
Ganjoo, K., Hong, F., Horning, S. J., Gascoyne, R. D., Natkunam, Y., & Advani, R. H. (2014). Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Leukemia & lymphoma, 55(4), 768-772.

Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404)
Ganjoo, K., Hong, F., Horning, S. J., Gascoyne, R. D., Natkunam, Y., & Advani, R. H. (2014). Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). LEUKEMIA & LYMPHOMA, 55(4), 768-772.

The Treatment Outcome for Adult Patients with Ewing's Sarcoma
Ganjoo, K. N., & Patel, S. (2013). The Treatment Outcome for Adult Patients with Ewing's Sarcoma. CURRENT ONCOLOGY REPORTS, 15(4), 372-377.

Soft Tissue Sarcoma, Version 2.2012 Featured Updates to the NCCN Guidelines
von Mehren, M., Benjamin, R. S., Bui, M. M., Casper, E. S., Conrad, E. U., & McMillian, N. R. (2012). Soft Tissue Sarcoma, Version 2.2012 Featured Updates to the NCCN Guidelines. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(8), 951-960.

Chest Wall Leiomyosarcoma After Breast-Conservative Therapy for Early-Stage Breast Cancer in a Young Woman With Li-Fraumeni Syndrome
Henry, E., Villalobos, V., Million, L., Jensen, K. C., West, R., & Telli, M. L. (2012). Chest Wall Leiomyosarcoma After Breast-Conservative Therapy for Early-Stage Breast Cancer in a Young Woman With Li-Fraumeni Syndrome. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 10(8), 939-942.

Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial
Advani, R. H., Hong, F., Horning, S. J., Kahl, B. S., Manola, J., & Ganjoo, K. (2012). Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial. LEUKEMIA & LYMPHOMA, 53(4), 718-720.

Maintenance Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced, Nonsquamous, Non-Small Cell Lung Cancer
Riess, J. W., Logan, A. C., Krupitskaya, Y., Padda, S., Clement-Duchene, C., & Wakelee, H. A. (2012). Maintenance Bevacizumab is Associated With Increased Hemoglobin in Patients With Advanced, Nonsquamous, Non-Small Cell Lung Cancer. CANCER INVESTIGATION, 30(3), 231-235.

Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in Fc gamma RIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma
Forero-Torres, A., de Vos, S., Pohlman, B. L., Pashkevich, M., Cronier, D. M., & Ganjoo, K. N. (2012). Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in Fc gamma RIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma. CLINICAL CANCER RESEARCH, 18(5), 1395-1403.

The Prognostic Value of Tumor-Associated Macrophages in Leiomyosarcoma A Single Institution Study
Ganjoo, K. N., Witten, D., Patel, M., Espinosa, I., La, T., & West, R. B. (2011). The Prognostic Value of Tumor-Associated Macrophages in Leiomyosarcoma A Single Institution Study. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 34(1), 82-86.

A Phase II First-Line Study of Gemcitabine, Carboplatin, and Bevacizumab in Advanced Stage Nonsquamous Non-small Cell Lung Cancer
Clement-Duchene, C., Krupitskaya, Y., Ganjoo, K., Lavori, P., McMillan, A., & Wakelee, H. A. (2010). A Phase II First-Line Study of Gemcitabine, Carboplatin, and Bevacizumab in Advanced Stage Nonsquamous Non-small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY, 5(11), 1821-1825.

I-131-Tositumomab (BexxarA (R)) vs. Y-90-Ibritumomab (ZevalinA (R)) Therapy of Low-Grade Refractory/Relapsed Non-Hodgkin Lymphoma
Iagaru, A., Mittra, E. S., Ganjoo, K., Knox, S. J., & Goris, M. L. (2010). I-131-Tositumomab (BexxarA (R)) vs. Y-90-Ibritumomab (ZevalinA (R)) Therapy of Low-Grade Refractory/Relapsed Non-Hodgkin Lymphoma. MOLECULAR IMAGING AND BIOLOGY, 12(2), 198-203.

Bendamustine Is Effective Therapy in Patients With Rituximab-Refractory, Indolent B-cell Non-Hodgkin Lymphoma Results From a Multicenter Study
Kahl, B. S., Bartlett, N. L., Leonard, J. P., Chen, L., Ganjoo, K., & Cheson, B. D. (2010). Bendamustine Is Effective Therapy in Patients With Rituximab-Refractory, Indolent B-cell Non-Hodgkin Lymphoma Results From a Multicenter Study. CANCER, 116(1), 106-114.

A phase II first line study of gemcitabine, carboplatin and bevacizumab in advanced stage non-squamous non-small cell lung cancer
Clement-Duchene, C., Krupitskaya, Y., Ganjoo, K., Lavori, P., Kumar, A., & Wakelee, H. (2009). A phase II first line study of gemcitabine, carboplatin and bevacizumab in advanced stage non-squamous non-small cell lung cancer. JOURNAL OF THORACIC ONCOLOGY, 4(9), S674-S674.

Coordinate Expression of Colony-Stimulating Factor-1 and Colony-Stimulating Factor-1-Related Proteins Is Associated with Poor Prognosis in Gynecological and Nongynecological Leiomyosarcoma
Espinosa, I., Beck, A. H., Lee, C.-H., Zhu, S., Montgomery, K. D., & van de Rijn, M. (2009). Coordinate Expression of Colony-Stimulating Factor-1 and Colony-Stimulating Factor-1-Related Proteins Is Associated with Poor Prognosis in Gynecological and Nongynecological Leiomyosarcoma. AMERICAN JOURNAL OF PATHOLOGY, 174(6), 2347-2356.

A phase II first-line study of gemcitabine, carboplatin, and bevacizumab (GCB) in advanced (adv) stage non-squamous non-small cell lung cancer (NSCLC)
Krupitskaya, Y., Ganjoo, K., Lavori, P. W., Kumar, A., Clement-Duchene, C., & Wakelee, H. A. (2009). A phase II first-line study of gemcitabine, carboplatin, and bevacizumab (GCB) in advanced (adv) stage non-squamous non-small cell lung cancer (NSCLC). JOURNAL OF CLINICAL ONCOLOGY, 27(15).

Breast Angiosarcoma: Case Series and Expression of Vascular Endothelial Growth Factor.
Brar, R., West, R., Witten, D., Raman, B., Jacobs, C., & Ganjoo, K. (2009). Breast Angiosarcoma: Case Series and Expression of Vascular Endothelial Growth Factor. Case reports in oncology, 2(3), 242-250.

Breast angiosarcomas: Case series and expression of vascular endothelial growth factor
Rondeep Brar, Robert West, Daniela Witten, Bhargav Raman, Charlotte Jacobs, & Kristen Ganjoo. (2009). Breast angiosarcomas: Case series and expression of vascular endothelial growth factor. Case Reports in Oncology, 2.

Opportunistic enteroviral meningoencephalitis: an unusual treatable complication of rituximab therapy
Ganjoo, K. N., Raman, R., Sobel, R. A., & Pinto, H. A. (2009). Opportunistic enteroviral meningoencephalitis: an unusual treatable complication of rituximab therapy. LEUKEMIA & LYMPHOMA, 50(4), 673-675.

The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients
Ganjoo, K. N., Moore, A. M., Orazi, A., Sen, J. A., Johnson, C. S., & An, C. S. (2008). The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 134(3), 381-387.

Review of erlotinib in the treatement of advanced non-small cell lung cancer
Kristen N Ganjoo, & Heather Wakelee. (2008). Review of erlotinib in the treatement of advanced non-small cell lung cancer. Biologics; Targets & Therapy.

Review of erlotinib in the treatment of advanced non-small cell lung cancer.
Ganjoo, K. N., & Wakelee, H. (2007). Review of erlotinib in the treatment of advanced non-small cell lung cancer. Biologics : targets & therapy, 1(4), 335-346.

Non-Hodgkin lymphoma of the breast
Ganjoo, K., Advani, R., Mariappan, M. R., McMillan, A., & Horning, S. (2007). Non-Hodgkin lymphoma of the breast. CANCER, 110(1), 25-30.

Antiangiogenesis: A new approach to the treatment of lymphoma
Ganjoo, K. (2007). Antiangiogenesis: A new approach to the treatment of lymphoma. LEUKEMIA & LYMPHOMA, 48(3), 454-455.

Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis
Ganjoo, K. N., An, C. S., Robertson, M. J., Gordon, L. I., Sen, J. A., & Horning, S. J. (2006). Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis. LEUKEMIA & LYMPHOMA, 47(6), 998-1005.

Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia
Frankel, A. E., Surendranathan, A., Black, J. H., White, A., Ganjoo, K., & Cripe, L. D. (2006). Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia. CANCER, 106(10), 2158-2164.

A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas - A hoosier oncology group study
Ganjoo, K. N., Robertson, M. J., Fisher, W., Jung, S. H., McClean, J., & Cripe, L. D. (2005). A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas - A hoosier oncology group study. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 28(2), 169-172.

Unusual locations of involvement by malignancies - Case 1. Testicular plasmacytoma
Shafqat, A., Yum, M. N., Abanour, R., & Ganjoo, K. N. (2003). Unusual locations of involvement by malignancies - Case 1. Testicular plasmacytoma. JOURNAL OF CLINICAL ONCOLOGY, 21(17), 3368-3369.

Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: A Hoosier Oncology Group study
Schneider, B. P., Ganjoo, K. N., Seitz, D. E., Picus, J., Fata, F., & Loehrer, P. J. (2003). Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: A Hoosier Oncology Group study. ONCOLOGY, 65(3), 218-223.

A phase I study of weekly gemcitabine and docetaxel in patients with advanced cancer: A Hoosier Oncology Group study
Ganjoo, K. N., GORDON, M. S., Sandler, A. B., Warner, R. E., Fife, K., & Loehrer, P. J. (2002). A phase I study of weekly gemcitabine and docetaxel in patients with advanced cancer: A Hoosier Oncology Group study. ONCOLOGY, 62(4), 299-304.

Germ cell tumor associated primitive neuroectodermal tumors
Ganjoo, K. N., Foster, R. S., Michael, H., Donohue, J. P., & Einhorn, L. H. (2001). Germ cell tumor associated primitive neuroectodermal tumors. JOURNAL OF UROLOGY, 165(5), 1514-1516.

Results of modern therapy for patients with mediastinal nonseminomatous germ cell tumors
Ganjoo, K. N., Rieger, K. M., Kesler, K. A., Sharma, M., Heilman, D. K., & Einhorn, L. H. (2000). Results of modern therapy for patients with mediastinal nonseminomatous germ cell tumors. CANCER, 88(5), 1051-1056.

Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma
Ganjoo, K. N., Chan, R. J., Sharma, M., & Einhorn, L. H. (1999). Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. JOURNAL OF CLINICAL ONCOLOGY, 17(11), 3457-3460.

Primary mediastinal nonseminomatous germ cell tumors: The influence of postchemotherapy pathology on long-term survival after surgery
Kesler, K. A., Rieger, K. M., Ganjoo, K. N., Sharma, M., Fineberg, N. S., & Brown, J. W. (1999). Primary mediastinal nonseminomatous germ cell tumors: The influence of postchemotherapy pathology on long-term survival after surgery. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 118(4), 692-700.

Lung cancer presenting with solitary bone metastases - Case 1: Metastatic adenocarcinoma to the patella
Ganjoo, K. N., Loyal, J. A., Cramer, H. M., & Loehrer, P. J. (1999). Lung cancer presenting with solitary bone metastases - Case 1: Metastatic adenocarcinoma to the patella. JOURNAL OF CLINICAL ONCOLOGY, 17(9), 2995-2997.

4.8 out of 5
139 Patient Ratings
15 Patient Comments

SHC Patient, Nov 2014

Dr. Ganjoo, her PA & RN are extraordinary people and very good at what they do!

SHC Patient, Oct 2014

I am very satisfied with all the spirit of services and attitude especially Dr. Ganjoo, Kristen N. ethics trusted and respected the spirit!

SHC Patient, Oct 2014

Left Stanford with a feeling that I would be in the best HANDS VA BAD.

SHC Patient, Sep 2014

Telephone call from the doctor on during holiday/decrease dosage, as promised by her nurse never happened. Off hour communication, such as by e-mails, was not good.

SHC Patient, Aug 2014

All Dr. Ganjoo's staff is great.

SHC Patient, Aug 2014

Dr. Ganjoo was very patient & understanding of my needs & concerns. I was extremely happy to have her as my MD.

SHC Patient, Aug 2014

Very good in everything.

SHC Patient, Jul 2014

Only issue was making assumptions re: CT scan results before they were final.

SHC Patient, Jun 2014

PA this time had difficulty with understanding problems/questions - ESL - heavy accent. MD was great.

SHC Patient, Jun 2014

Provide great care, and have great people at Stanford.

SHC Patient, Apr 2014

Listens & explains & examined. Could take a week or more to call me back.

SHC Patient, Mar 2014

Dr. K. Ganjoo is tops in her field and I was honored to be able to see her.

SHC Patient, Feb 2014

Dr. Ganjoo was extremely attentive and explained/answered at.... all my questions.

SHC Patient, Jan 2014

Best service every time.

SHC Patient, Dec 2013

Provider always gives hope.